September 2026
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
ETHAN Trial: Rethinking Endocrine Therapy for Men's Breast Cancer
3
Taking Weekends Off Dasatinib Maintains Responses in First-Line CML
4
Contrasting Myeloma Therapies for Late Relapse in Patient Declining CAR T
5
